Shell Asset Management Co. trimmed its position in shares of Humana Inc (NYSE:HUM) by 6.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 19,854 shares of the insurance provider’s stock after selling 1,358 shares during the quarter. Shell Asset Management Co.’s holdings in Humana were worth $6,235,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the business. Integrated Advisors Network LLC grew its stake in Humana by 3.3% during the first quarter. Integrated Advisors Network LLC now owns 919 shares of the insurance provider’s stock worth $289,000 after buying an additional 29 shares during the last quarter. Bessemer Group Inc. grew its stake in Humana by 6.0% during the first quarter. Bessemer Group Inc. now owns 532 shares of the insurance provider’s stock worth $167,000 after buying an additional 30 shares during the last quarter. First Bank & Trust grew its stake in Humana by 4.3% during the first quarter. First Bank & Trust now owns 759 shares of the insurance provider’s stock worth $239,000 after buying an additional 31 shares during the last quarter. Citizens Financial Group Inc RI grew its stake in Humana by 2.9% during the first quarter. Citizens Financial Group Inc RI now owns 1,188 shares of the insurance provider’s stock worth $374,000 after buying an additional 33 shares during the last quarter. Finally, Vident Investment Advisory LLC lifted its position in shares of Humana by 0.8% during the fourth quarter. Vident Investment Advisory LLC now owns 4,338 shares of the insurance provider’s stock worth $1,590,000 after purchasing an additional 36 shares in the last quarter. 93.22% of the stock is currently owned by hedge funds and other institutional investors.
HUM traded down $0.84 during mid-day trading on Friday, hitting $394.43. The stock had a trading volume of 415,854 shares, compared to its average volume of 962,079. The stock’s fifty day simple moving average is $361.93 and its 200-day simple moving average is $345.82. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.66 and a quick ratio of 1.66. The firm has a market capitalization of $52.26 billion, a price-to-earnings ratio of 20.25, a price-to-earnings-growth ratio of 1.73 and a beta of 0.91. Humana Inc has a 1-year low of $208.25 and a 1-year high of $412.70.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.625 dividend. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.50 annualized dividend and a yield of 0.63%. Humana’s dividend payout ratio (DPR) is presently 13.99%.
In other Humana news, Director David A. Jr/Ky Jones sold 5,800 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $256.19, for a total value of $1,485,902.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.42% of the company’s stock.
HUM has been the topic of a number of research reports. SunTrust Banks upped their target price on shares of Humana from $400.00 to $440.00 and gave the stock a “hold” rating in a research report on Thursday. Morgan Stanley upped their target price on shares of Humana from $375.00 to $500.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Mizuho upped their target price on shares of Humana from $405.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Barclays reiterated a “buy” rating on shares of Humana in a research report on Sunday, March 29th. Finally, Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating and set a $396.00 target price on the stock. in a research report on Friday, April 17th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $405.42.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Strangles
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.